-
Ultimovacs ASA Reports Second Quarter 2024 Financial Results and Provides General Business Update
-
Ultimovacs ASA Reports Second Quarter 2024 Financial Results and Provides General Business Update
-
Ultimovacs ASA: Invitation to second quarter 2024 results webcast presentation
-
Ultimovacs ASA: Invitation to second quarter 2024 results webcast presentation
-
Ultimovacs Announces Notice of Resignation from Deputy Board Member
-
Ultimovacs Announces Notice of Resignation from Deputy Board Member
-
Ultimovacs Announces Topline Data from FOCUS Phase II Trial of UV1 Combined with Pembrolizumab in Patients with Metastatic or Recurrent Head and Neck Cancer
-
Ultimovacs Announces Topline Data from FOCUS Phase II Trial of UV1 Combined with Pembrolizumab in Patients with Metastatic or Recurrent Head and Neck Cancer
-
Ultimovacs Announces Poster Presentation of NIPU Phase II Trial Update at Upcoming ESMO Congress 2024
-
Ultimovacs Announces Poster Presentation of NIPU Phase II Trial Update at Upcoming ESMO Congress 2024
